The monograph excludes certain specialized forms from its direct requirements: .
Before a tablet ever reaches a patient, it must survive manufacturing, bottling, shipping, and handling. This is where the physical attributes described in 0478 come into play.
: Formulated with special excipients or specific procedures to modify the rate, site, or time of active substance release. This encompasses both prolonged-release and delayed-release profiles.
Tablets must have sufficient strength to resist crumbling or breaking during handling and shipping. This is often assessed via Friability (2.9.7) and Resistance to Crushing (2.9.8) tests. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
: Designed to dissolve in water with the release of carbon dioxide.
The manufacturing process for tablets involves several steps, including:
In the world of modern medicine, the tablet is the undisputed king. It is the default delivery system for the vast majority of active pharmaceutical ingredients (APIs). Yet, behind every unassuming white disc lies a complex engineering challenge: how do you ensure that a powder becomes a solid, survives the journey in a bottle, and then dissolves perfectly inside the human body? The monograph excludes certain specialized forms from its
Basic compressed units; must disintegrate within 15 minutes unless otherwise justified.
Dissolution testing evaluates the rate at which the API is released from the tablet matrix into a liquid medium, simulating human physiological conditions. This is a critical surrogate marker for in vivo drug absorption and bioavailability. Modified-release and gastro-resistant tablets require highly specialized dissolution profiles (e.g., testing in acid medium followed by a buffer change). C. Disintegration (2.9.1)
| Test | Ph. Eur. Reference | When required | Common Pitfall | |------|--------------------|---------------|----------------| | Appearance | Visual inspection | Always | Overlooking color variation from batch to batch | | Identification A+B | As per monograph | Always | Using same HPLC condition for assay and ID (not allowed unless specified) | | Uniformity of mass | 2.9.5 | If active ≥ 50% w/w or ≥ 25 mg per unit | Not performing it on 20 tablets individually | | Uniformity of content | 2.9.6 | If active < 50% w/w or < 2 mg per unit | Applying mass method incorrectly to low-dose tablets | | Dissolution | 2.9.3 | Default for immediate-release | Using wrong apparatus (paddle vs basket) without justification | | Disintegration | 2.9.1 | Only if monograph permits | Forgetting time limit (e.g., 15 min for uncoated) | | Friability | 2.9.7 | Only if in specification | Testing hygroscopic tablets at ambient humidity | : Formulated with special excipients or specific procedures
Monograph 0478 states that impurities come from two sources:
For solid dosage forms, the active substance must be released and absorbed to be effective. The monograph gives priority to the Dissolution Test (2.9.3) , which measures the percentage of drug released into a specified medium over time (e.g., 80% in 30 minutes). For rapidly dissolving tablets of highly soluble drugs, a Disintegration Test (2.9.1) may be substituted, where tablets are placed in a basket-rack assembly in water at 37°C and must disintegrate within a specified time (e.g., 15 minutes for uncoated tablets). For enteric-coated tablets, the monograph specifies two stages: resistance to disintegration in acidic medium (simulating stomach), followed by disintegration in neutral buffer (simulating intestine).
The monograph explicitly excludes preparations like lozenges, oral pastes, and oral gums , which are covered under separate general chapters such as Oromucosal Preparations (1807).